AAAAAA

   
Results: 1-25 | 26-29
Results: 1-25/29
AMINOPEPTIDASE-A EXPRESSION AND ENZYMATIC-ACTIVITY IN PRIMARY HUMAN RENAL CANCERS
Authors: NANUS DM BOGENRIEDER T PAPANDREOU CN FINSTAD CL BANDER NH LEE A VLAMIS V MOTZER RJ ALBINO AP REUTER VE
Citation: Dm. Nanus et al., AMINOPEPTIDASE-A EXPRESSION AND ENZYMATIC-ACTIVITY IN PRIMARY HUMAN RENAL CANCERS, International journal of oncology, 13(2), 1998, pp. 261-267
METASTATIC GERM-CELL TUMORS - MODELING FOR RESPONSE TO CHEMOTHERAPY
Authors: BAJORIN DF MAZUMDAR M MEYERS M MOTZER RJ VLAMIS V LIN P BOSL GJ
Citation: Df. Bajorin et al., METASTATIC GERM-CELL TUMORS - MODELING FOR RESPONSE TO CHEMOTHERAPY, Journal of clinical oncology, 16(2), 1998, pp. 707-715
ANATOMIC SITE OF PRIMARY TRANSITIONAL-CELL CARCINOMA (TCC) DOES NOT AFFECT PROBABILITY OF RESPONSE TO M-VAC OR SURVIVAL
Authors: MCCAFFREY JA DODD PM HERR H VLAMIS V MAZUMDAR M HIGGINS G SCHER HI BAJORIN DF
Citation: Ja. Mccaffrey et al., ANATOMIC SITE OF PRIMARY TRANSITIONAL-CELL CARCINOMA (TCC) DOES NOT AFFECT PROBABILITY OF RESPONSE TO M-VAC OR SURVIVAL, The Journal of urology, 159(5), 1998, pp. 634-634
POSTCHEMOTHERAPY SURGERY AFTER M-VAC IN PATIENTS (PTS) WITH METASTATIC TRANSITIONAL-CELL CARCINOMA (TCC) CAN RESULT IN LONG-TERM SURVIVAL
Authors: DODD PM MCCAFFREY JA HERR H VLAMIS V MAZUMDAR M HIGGINS G SCHER HI BAJORIN DF
Citation: Pm. Dodd et al., POSTCHEMOTHERAPY SURGERY AFTER M-VAC IN PATIENTS (PTS) WITH METASTATIC TRANSITIONAL-CELL CARCINOMA (TCC) CAN RESULT IN LONG-TERM SURVIVAL, The Journal of urology, 159(5), 1998, pp. 636-636
DIFFERENTIATED THYROID-CANCER - DETERMINANTS OF DISEASE PROGRESSION IN PATIENTS LESS-THAN-21 YEARS OF AGE AT DIAGNOSIS - A REPORT FROM THE SURGICAL DISCIPLINE COMMITTEE OF THE CHILDRENS-CANCER-GROUP
Authors: NEWMAN KD BLACK T HELLER G AZIZKHAN RG HOLCOMB GW SKLAR C VLAMIS V HAASE GM LAQUAGLIA MP
Citation: Kd. Newman et al., DIFFERENTIATED THYROID-CANCER - DETERMINANTS OF DISEASE PROGRESSION IN PATIENTS LESS-THAN-21 YEARS OF AGE AT DIAGNOSIS - A REPORT FROM THE SURGICAL DISCIPLINE COMMITTEE OF THE CHILDRENS-CANCER-GROUP, Annals of surgery, 227(4), 1998, pp. 533-541
HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN FIRST-LINE THERAPY FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS
Authors: MOTZER RJ MAZUMDAR M BAJORIN DF BOSL GJ LYN P VLAMIS V
Citation: Rj. Motzer et al., HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN FIRST-LINE THERAPY FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS, Journal of clinical oncology, 15(7), 1997, pp. 2546-2552
LONG-TERM FOLLOW-UP OF PATIENTS WITH GOOD-RISK GERM-CELL TUMORS TREATED WITH ETOPOSIDE AND CISPLATIN
Authors: XIAO H MAZUMDAR M BAJORIN DF SAROSDY M VLAMIS V SPICER J FERRARA J BOSL GJ MOTZER RJ
Citation: H. Xiao et al., LONG-TERM FOLLOW-UP OF PATIENTS WITH GOOD-RISK GERM-CELL TUMORS TREATED WITH ETOPOSIDE AND CISPLATIN, Journal of clinical oncology, 15(7), 1997, pp. 2553-2558
IFOSFAMIDE-CONTAINING AND CISPLATIN-CONTAINING CHEMOTHERAPY AS FIRST-LINE SALVAGE THERAPY IN GERM-CELL TUMORS - RESPONSE AND SURVIVAL
Authors: MCCAFFREY JA MAZUMDAR M BAJORIN DF BOSL GJ VLAMIS V MOTZER RJ
Citation: Ja. Mccaffrey et al., IFOSFAMIDE-CONTAINING AND CISPLATIN-CONTAINING CHEMOTHERAPY AS FIRST-LINE SALVAGE THERAPY IN GERM-CELL TUMORS - RESPONSE AND SURVIVAL, Journal of clinical oncology, 15(7), 1997, pp. 2559-2563
A PHASE-II STUDY OF 13-CIS-RETINOIC ACID IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
Authors: BERG WJ SCHWARTZ LH AMSTERDAM A MAZUMDAR M VLAMIS V LAW TM NANUS DM MOTZER RJ
Citation: Wj. Berg et al., A PHASE-II STUDY OF 13-CIS-RETINOIC ACID IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Investigational new drugs, 15(4), 1997, pp. 353-355
HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE FOR PATIENTS WITH REFRACTORY GERM-CELL TUMORS - TREATMENT RESULTS AND PROGNOSTIC FACTORS FOR SURVIVAL AND TOXICITY
Authors: MOTZER RJ MAZUMDAR M BOSL GJ BAJORIN DF AMSTERDAM A VLAMIS V
Citation: Rj. Motzer et al., HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE FOR PATIENTS WITH REFRACTORY GERM-CELL TUMORS - TREATMENT RESULTS AND PROGNOSTIC FACTORS FOR SURVIVAL AND TOXICITY, Journal of clinical oncology, 14(4), 1996, pp. 1098-1105
MANAGEMENT OF RESIDUAL MASS IN ADVANCED SEMINOMA - RESULTS AND RECOMMENDATIONS FROM THE MEMORIAL SLOAN-KETTERING CANCER CENTER
Authors: PUC HS HEELAN R MAZUMDAR M HERR H SCHEINFELD J VLAMIS V BAJORIN DF BOSL GJ MENCEL P MOTZER RJ
Citation: Hs. Puc et al., MANAGEMENT OF RESIDUAL MASS IN ADVANCED SEMINOMA - RESULTS AND RECOMMENDATIONS FROM THE MEMORIAL SLOAN-KETTERING CANCER CENTER, Journal of clinical oncology, 14(2), 1996, pp. 454-460
CHEMOTHERAPY WITHOUT IRRADIATION - A NOVEL-APPROACH FOR NEWLY-DIAGNOSED CNS GERM-CELL TUMORS - RESULTS OF AN INTERNATIONAL COOPERATIVE TRIAL
Authors: BALMACEDA C HELLER G ROSENBLUM M DIEZ B VILLABLANCA JG KELLIE S MAHER P VLAMIS V WALKER RW LEIBEL S FINLAY JL
Citation: C. Balmaceda et al., CHEMOTHERAPY WITHOUT IRRADIATION - A NOVEL-APPROACH FOR NEWLY-DIAGNOSED CNS GERM-CELL TUMORS - RESULTS OF AN INTERNATIONAL COOPERATIVE TRIAL, Journal of clinical oncology, 14(11), 1996, pp. 2908-2915
ACID-PHOSPHATASE - DEFINING A ROLE IN ANDROGEN-INDEPENDENT PROSTATE-CANCER
Authors: STEINECK G KELLY WK MAZUMDAR M VLAMIS V SCHWARTZ M SCHER HI
Citation: G. Steineck et al., ACID-PHOSPHATASE - DEFINING A ROLE IN ANDROGEN-INDEPENDENT PROSTATE-CANCER, Urology, 47(5), 1996, pp. 719-726
SURAMIN AND HYDROCORTISONE - DETERMINING DRUG EFFICACY IN ANDROGEN-INDEPENDENT PROSTATE-CANCER
Authors: KELLY WK SCHER HI MAZUMDAR M PFISTER D CURLEY T LEIBERTZ C COHEN L VLAMIS V DNISTRIAN A SCHWARTZ M
Citation: Wk. Kelly et al., SURAMIN AND HYDROCORTISONE - DETERMINING DRUG EFFICACY IN ANDROGEN-INDEPENDENT PROSTATE-CANCER, Journal of clinical oncology, 13(9), 1995, pp. 2214-2222
INTERFERON ALFA-2A AND 13-CIS-RETINOIC ACID IN RENAL-CELL CARCINOMA -ANTITUMOR-ACTIVITY IN A PHASE-II TRIAL AND INTERACTIONS IN-VITRO
Authors: MOTZER RJ SCHWARTZ L LAW TM MURPHY BA HOFFMAN AD ALBINO AP VLAMIS V NANUS DM
Citation: Rj. Motzer et al., INTERFERON ALFA-2A AND 13-CIS-RETINOIC ACID IN RENAL-CELL CARCINOMA -ANTITUMOR-ACTIVITY IN A PHASE-II TRIAL AND INTERACTIONS IN-VITRO, Journal of clinical oncology, 13(8), 1995, pp. 1950-1957
ETOPOSIDE AND CISPLATIN ADJUVANT THERAPY FOR PATIENTS WITH PATHOLOGICAL STAGE-II GERM-CELL TUMORS
Authors: MOTZER RJ SHEINFELD J MAZUMDAR M BAJORIN DF BOSL GJ HERR H LYN P VLAMIS V
Citation: Rj. Motzer et al., ETOPOSIDE AND CISPLATIN ADJUVANT THERAPY FOR PATIENTS WITH PATHOLOGICAL STAGE-II GERM-CELL TUMORS, Journal of clinical oncology, 13(11), 1995, pp. 2700-2704
QUALITY-OF-LIFE OF WOMEN WITH OVARIAN-CANCER
Authors: KORNBLITH AB THALER HT WONG G VLAMIS V LEPORE JM LOSETH DB HAKES T HOSKINS WJ PORTENOY RK
Citation: Ab. Kornblith et al., QUALITY-OF-LIFE OF WOMEN WITH OVARIAN-CANCER, Gynecologic oncology, 59(2), 1995, pp. 231-242
CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA PATIENTS WITH A DOCUMENTEDPREVIOUSLY COMPLETE SURGICAL RESPONSE
Authors: VACCARELLO L RUBIN SC VLAMIS V WONG G JONES WB LEWIS JL HOSKINS WJ
Citation: L. Vaccarello et al., CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA PATIENTS WITH A DOCUMENTEDPREVIOUSLY COMPLETE SURGICAL RESPONSE, Gynecologic oncology, 57(1), 1995, pp. 61-65
PHASE-III RANDOMIZED TRIAL OF INTERLEUKIN-2 WITH OR WITHOUT LYMPHOKINE-ACTIVATED KILLER-CELLS IN THE TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
Authors: LAW TM MOTZER RJ MAZUMDAR M SELL KW WALTHER PJ OCONNELL M KHAN A VLAMIS V VOGELZANG NJ BAJORIN DF
Citation: Tm. Law et al., PHASE-III RANDOMIZED TRIAL OF INTERLEUKIN-2 WITH OR WITHOUT LYMPHOKINE-ACTIVATED KILLER-CELLS IN THE TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Cancer, 76(5), 1995, pp. 824-832
ADVANCED SEMINOMA - TREATMENT RESULTS, SURVIVAL, AND PROGNOSTIC FACTORS IN 142 PATIENTS
Authors: MENCEL PJ MOTZER RJ MAZUMDAR M VLAMIS V BAJORIN DF BOSL GJ
Citation: Pj. Mencel et al., ADVANCED SEMINOMA - TREATMENT RESULTS, SURVIVAL, AND PROGNOSTIC FACTORS IN 142 PATIENTS, Journal of clinical oncology, 12(1), 1994, pp. 120-126
TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES
Authors: BARAKAT RR WONG G CURTIN JP VLAMIS V HOSKINS WJ
Citation: Rr. Barakat et al., TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES, Gynecologic oncology, 55(2), 1994, pp. 164-168
PAIN IN OVARIAN-CANCER PATIENTS - PREVALENCE, CHARACTERISTICS, AND ASSOCIATED SYMPTOMS
Authors: PORTENOY RK KORNBLITH AB WONG G VLAMIS V LEPORE JM LOSETH DB HAKES T FOLEY KM HOSKINS WJ
Citation: Rk. Portenoy et al., PAIN IN OVARIAN-CANCER PATIENTS - PREVALENCE, CHARACTERISTICS, AND ASSOCIATED SYMPTOMS, Cancer, 74(3), 1994, pp. 907-915
SERUM TUMOR-MARKER DECLINE IS AN EARLY PREDICTOR OF TREATMENT OUTCOMEIN GERM-CELL TUMOR PATIENTS TREATED WITH CISPLATIN AND IFOSFAMIDE SALVAGE CHEMOTHERAPY
Authors: MURPHY BA MOTZER RJ MAZUMDAR M VLAMIS V NISSELBAUM J BAJORIN D BOSL GJ
Citation: Ba. Murphy et al., SERUM TUMOR-MARKER DECLINE IS AN EARLY PREDICTOR OF TREATMENT OUTCOMEIN GERM-CELL TUMOR PATIENTS TREATED WITH CISPLATIN AND IFOSFAMIDE SALVAGE CHEMOTHERAPY, Cancer, 73(10), 1994, pp. 2520-2526
THE EFFECT OF AGE AT DIAGNOSIS ON OUTCOME IN RHABDOMYOSARCOMA
Authors: LAQUAGLIA MP HELLER G GHAVIMI F CASPER ES VLAMIS V HAJDU S BRENNAN MF
Citation: Mp. Laquaglia et al., THE EFFECT OF AGE AT DIAGNOSIS ON OUTCOME IN RHABDOMYOSARCOMA, Cancer, 73(1), 1994, pp. 109-117
PHASE-II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUSBONE-MARROW TRANSPLANTATION IN 1ST-LINE THERAPY FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS
Authors: MOTZER RJ MAZUMDAR M GULATI SC BAJORIN DF LYN P VLAMIS V BOSL GJ
Citation: Rj. Motzer et al., PHASE-II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUSBONE-MARROW TRANSPLANTATION IN 1ST-LINE THERAPY FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS, Journal of the National Cancer Institute, 85(22), 1993, pp. 1828-1835
Risultati: 1-25 | 26-29